Elicio Therapeutics terminates Chief Business Officer Annette Matthies without cause

Elicio Therapeutics, Inc.

Annette Matthies, Ph.D., Chief Business Officer, terminated without cause effective October 5, 2023.
No replacement or interim successor named in the filing.
Separation is effective as of the date of termination.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Annette Matthies

Chief Business Officer

ELTX · Elicio Therapeutics, Inc.

Effective: 2023-10-05
Filed: October 12, 2023, 7:59 PM ET

On October 5, 2023, Annette Matthies, Ph.D., Chief Business Officer of Elicio Therapeutics, Inc. (the “Company”) was terminated without cause, effective as of the same date (the “Separation Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Annette Matthies departed as Chief Business Officer at Elicio Therapeutics, Inc..

Action: terminated without cause
Role: Chief Business Officer

Exact text from the filing

On October 5, 2023, Annette Matthies, Ph.D., Chief Business Officer of Elicio Therapeutics, Inc. (the “Company”) was terminated without cause, effective as of the same date (the “Separation Date”).

View on SEC.gov

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-23-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.